Skip Ribbon Commands
Skip to main content

News release


Jones Lang LaSalle Awarded Sales Assignment for Pharmaceutical Campus in Virginia

State-of-the-art Active Pharmaceutical Ingredient (API) production campus

RICHMOND, Va., Jan. 21, 2014 – Jones Lang LaSalle announced today that it has been selected by Germany-based Boehringer Ingelheim, one of the world’s 20 leading pharmaceutical companies, to sell the world-class, multi-purpose pharmaceutical production campus at 2820 N. Normandy Drive in Petersburg, VA.

Boehringer Ingelheim developed the 190-acre campus, located about 25 miles south of Richmond, Virginia's state capital, for the manufacture of Active Pharmaceutical Ingredients (API) for human, veterinary and clinical research use. Current production occupies approximately 85 acres on the site.

Boehringer Ingelheim has continuously upgraded the facility since its inception in 1977, including a significant expansion in 2009 that delivered state-of-the-art production technology.

Highly compliant with stringent cGMP requirements, the campus meets DEA regulations for on-site production of Class II substances and is suitable for the ongoing production of API, specialty chemicals, nutriceuticals and chemical intermediates.
“Boehringer Ingelheim awarded Jones Lang LaSalle this exclusive assignment because of our global capabilities, successful track record within our Life Science Practice Group and the firm’s capacity to effectively manage complex transactions,” said Stan Manoogian, Senior Vice President in the Richmond, VA, office of Jones Lang LaSalle and project leader for this assignment.

This extremely well maintained campus is fully equipped with pharmaceutical research, quality control, a pilot plant scale for development and a Kilo lab. The campus has integrated utility, production, wastewater and emission control infrastructure, and four synthesis buildings that support diverse, automated, multi-product manufacturing.

Additionally, the campus offers full administrative, maintenance, safety and warehouse facilities on site, including a corporate office building, a clinic, fitness center and cafeteria. The balance of the land is available for expansion or alternate related uses, and a portion of the site includes available access to the adjacent Norfolk Southern rail service. There are four existing controlled site entrances, which allow the campus to be subdivided for multiple users. Production by Boehringer Ingelheim runs through June 2014.

About Boehringer Ingelheim
Boehringer Ingelheim operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

About Jones Lang LaSalle
Jones Lang LaSalle (NYSE:JLL) is a professional services and investment management firm offering specialized real estate services to clients seeking increased value by owning, occupying and investing in real estate. With annual revenue of $3.9 billion, Jones Lang LaSalle operates in 70 countries from more than 1,000 locations worldwide. On behalf of its clients, the firm provides management and real estate outsourcing services to a property portfolio of 2.6 billion square feet and completed $63 billion in sales, acquisitions and finance transactions in 2012. Its investment management business, LaSalle Investment Management, has $46.7 billion of real estate assets under management. For further information, visit